Pharma Update

Polivy: Accelerated growth following 1L DLBCL approval Transforming the standard of care in 1L DLBCL again after 20 years Global Polivy sales Polivy performance update CHFM 400 300 200 >500% +17% 100 +91% YoY CER growth • +114% • Currently approved in >80 countries in 1L DLBCL Roche POLIVY polatuzumab vedotin • . Strong 1L DLBCL uptake especially in US, EU and JP Growing patient shares in 1L DLBCL (IPI 0-5), US 13%, Germany 21%, UK 26% and Japan 32% Updated treatment guidelines established Polivy as standard of care in 1L DLBCL in key markets such as US (NCCN category 1), Germany and Japan Outlook • Further growth expected driven by additional approvals and positive reimbursement decisions in EU and international markets Comprehensive development program, including Polivy combinations in 1L/2L+ DLBCL with first-in-class bispecifics Lunsumio and Columvi 0 . HY 20 HY 21 HY 22 HY 23 US Europe International Japan CER=constant exchange rates; DLBCL-diffuse large B-cell lymphoma; IPI=International prognostic index; NCCN=National Comprehensive Cancer Network; Polivy in collaboration with Seagen 58

View entire presentation